Skyview Ventures http://www.skyviewcapital.com/home/ventures/, the early and growth stage investment arm of global private investment firm Skyview Capital, LLC, has completed its seed round investment in Pr3vent, Inc. (“Pr3vent”).
|
LOS ANGELES, /PRNewswire/ -- Skyview Ventures http://www.skyviewcapital.com/home/ventures/, the early and growth stage investment arm of global private investment firm Skyview Capital, LLC, has completed its seed round investment in Pr3vent, Inc. ("Pr3vent"). Pr3vent is a Palo Alto, California-based healthcare technology company founded by noted medical field veterans Jochen Kumm, PhD and Darius M. Moshfeghi, MD. Further expanding Skyview Ventures' interests in disruptive biotechnology companies, the seed round financing will accelerate Pr3vent, Inc.'s development of the company's revolutionary eye screening diagnostic service designed expressly for newborns. Skyview is joined in the investment by Phillip Sarofim and his private equity/venture capital firm Trousdale Ventures, LLC (formerly PS Ventures). The joint investment by Skyview Capital and Sarofim's Trousdale Ventures in Pr3vent marks the continuation of the two firms' collaboration with select start-up and first phase companies. Pr3vent's breakthrough technology introduces an Artificial Intelligence algorithm that provides early diagnosis and intervention to help allow for eye problems to be more effectively treatable by existing modalities. The investment in Pr3vent marks Skyview's eighth venture investment since launching the firm's asset class in January 2017, signifying its aggressive and robust activity within this sector to date, and further aligning it with the firm's deep expertise in technology and biotechnology, software, and differentiated consumer products and solutions. Additional Skyview Ventures early and growth stage investments include KangarooTime, HopSkipDrive, BuyitInstalled, Kitul SuperCoffee, SilkTech, and OnPoint Global. "We are very excited to partner with Darius and Jochen and help bring this remarkable, potentially life enhancing diagnostic tool to the forefront of pediatric healthcare. It has long been common practice for immediate newborns to be screened for hearing, and now as a direct result of the successful research by Pr3vent principals, Dr. Kumm and Dr. Moshfeghi, it is finally possible to screen for vision when infants are first born as well. We see the Pr3vent technology platform as a true game-changer in healthcare diagnostics," said Alex Soltani, Chairman and Chief Executive Officer of Skyview. "I am pleased to join side by side with Skyview Capital in completing our Pr3vent investment. The work of principals Dr. Kumm and Dr. Moshfeghi is truly groundbreaking and has a tremendous potential of impacting the eye health of infants worldwide," said Phillip Sarofim, President and Chief Executive Officer of PS Ventures. "We are excited to partner with Skyview and take Pr3vent to the next level. Pr3vent's AI screening platform will improve health outcomes first in newborns and then in other healthcare use cases," said Dr. Kumm, Chief Executive Officer of Pr3vent. "We are thrilled to have Skyview Capital join as our first institutional investor. Their knowledge and contacts in the software and cloud services sector complement our strengths in deep learning, pediatric eye diseases, and the screening market. We hope to leverage our combined expertise for operational and strategic advantage," said Pr3vent partner Dr. Moshfeghi. Dr. Kumm has worked in computation and AI at the Stanford Genome Technology Center, IBM Watson Life Sciences, insightAI, Pathogenica, and Roche Pharma. He has a BA from Harvard and a PhD in Biological Sciences from Stanford. Dr. Moshfeghi is the Director of Retina at the Byers Eye Institute, Horngren Family Vitreoretinal Center, Stanford University School of Medicine. His career has focused on expanding care to pediatric eyes using telemedicine. He currently serves on the Telemedicine Working Group for the American Academy of Ophthalmology. He serves on several corporate boards including 1800 Contacts, dSentz, and Promisght. He leads the Scientific Advisory Board for Visunex Medical Systems, Co. Ltd which makes a pediatric camera used for pediatric eye screening. About Skyview Ventures About Skyview Capital, LLC Trousdale Ventures, LLC About Pr3vent, Inc.
SOURCE Skyview Capital, LLC |
View original content:
